The Venture Capital Podcast with Fexingo: VCs, Term Sheets, and Startup Investing

The Venture Capital Podcast with Fexingo: VCs, Term Sheets, and Startup Investing

By FexingoBusiness
Download on the App Store

The Venture Capital Podcast with Fexingo: VCs, Term Sheets, and Startup Investing episodes

  • Why VCs Are Investing in Defense Tech Startups

    Episode 77 of The Venture Capital Podcast with Fexingo dives into the booming defense tech sector in 2026. Lucas and Luna explore why venture capital is flowing into startups building military and security solutions, from AI-powered surveillance to autonomous drones. They examine recent headlines like the FTC's approval of Musk's acquisition of SpaceX alumni startup Mesh and the Trump administration's release of Anthropic's Mythos tool to over 100 US companies and agencies. The hosts discuss the ethical dilemmas, the shift from commercial-only portfolios, and the specific metrics VCs use to evaluate defense startups, including government contract cycles and regulatory hurdles. They also touch on the growing trend of dual-use technologies that serve both military and civilian markets. With concrete examples and market context—like Palantir's stock at $112.93—Lucas and Luna debate whether defense tech is the next big venture wave or a risky bet on geopolitics. Plus, a brief note on how listener support keeps the show ad-free.

    #DefenseTech #VentureCapital #DefenseStartups #AI #Musk #Mesh #Anthropic #Mythos #Palantir #GovernmentContracts #DualUse #Geopolitics #AutonomousDrones #Surveillance #FTC #TechInvesting #FexingoBusiness #BusinessPodcast

    Keep every episode free: buymeacoffee.com/fexingo

    9 min
  • Why VCs Are Betting on Gene Therapy Manufacturing in 2026

    Episode 76 of The Venture Capital Podcast. Lucas and Luna explore why top venture capital firms are pouring hundreds of millions into gene therapy manufacturing — a space historically dominated by a few contract development and manufacturing organizations (CDMOs). They zero in on the specific bottleneck: viral vector production, which costs startups up to $400,000 per batch and can delay clinical trials by over a year. Lucas breaks down the economics, citing recent data that the gene therapy manufacturing market could exceed $10 billion by 2028, and why VCs see this as a competitive moat, not just a service. Luna pushes back on the hype, questioning whether manufacturing startups can scale profitably or if they'll be squeezed by big pharma. They also touch on how the recent 11.6% surge in the ARKG genomics ETF reflects renewed investor confidence in the sector. The hosts keep it concrete with examples of startups tackling adeno-associated virus (AAV) production and lipid nanoparticle formulation. No fluff — just the numbers and strategy behind a quiet but massive pivot in venture capital.

    #GeneTherapy #Manufacturing #VCInvesting #ViralVectors #AAV #Biotech #ARKG #CDMO #Startups #VentureCapital #Business #Technology #Podcast #FexingoBusiness #BusinessPodcast #LucasAndLuna #LifeSciences #ScaleUp

    Keep every episode free: buymeacoffee.com/fexingo

    8 min
  • Why VCs Are Betting on Gene Therapy Manufacturing

    Episode 75 of The Venture Capital Podcast dives into a quiet but massive shift in biotech venture capital: gene therapy manufacturing. While most headlines chase AI and crypto, VCs are placing billion-dollar bets on the infrastructure that produces living drugs. Lucas and Luna unpack why gene therapy factories are the new semiconductor fabs, with a focus on the recent $200 million Series C for a stealthy contract development and manufacturing organization (CDMO) in Basel. They tie in the week's market data, including ARKG's 8.8% gain versus the broader tech selloff, and explain why manufacturing capacity is the bottleneck keeping gene therapies from becoming blockbusters. The conversation covers unit economics, regulatory tailwinds, and the critical distinction between viral vector platforms and traditional biologics manufacturing. A practical look at where VC dollars are flowing when no one is watching.

    #GeneTherapy #BiotechVC #CDMO #ViralVectors #Manufacturing #ARKG #Basel #SeriesC #UnitEconomics #RegulatoryTailwinds #LivingDrugs #Infrastructure #Therapeutics #VentureCapital #Podcast #FexingoBusiness #BusinessPodcast #Investing

    Keep every episode free: buymeacoffee.com/fexingo

    13 min
  • Why VCs Are Betting on Energy Startups in 2026

    This episode of The Venture Capital Podcast digs into a quiet shift in venture capital: energy infrastructure. Lucas and Luna look at a16z-backed Base Power, which is offering cheaper electricity to the grid, and the broader thesis that VCs are moving beyond pure software into hard-tech energy plays. They discuss why the AI data-center boom is driving demand for new power sources, how startups like Base Power are positioning themselves as grid partners rather than disruptors, and what this means for founders building energy-hardware companies. Along the way, they touch on Palantir's recent drop and the ARKG genomics ETF's surprising rally as contrasting signals in the market. The conversation is grounded in the specific numbers and strategies shaping this emerging venture category.

    #VentureCapital #EnergyStartups #BasePower #a16z #GridInfrastructure #ClimateTech #AIDataCenters #HardTech #StartupInvesting #Business #Technology #SeriesA #Palantir #ARKG #Genomics #CleanEnergy #FexingoBusiness #BusinessPodcast

    Keep every episode free: buymeacoffee.com/fexingo

    8 min
  • Why VCs Are Moving From Fundraising to Fund Operations

    In episode 73 of The Venture Capital Podcast, Lucas and Luna examine a quiet shift in how venture firms spend their time: the move from constant fundraising toward building fund operations teams. Using recent data on ARK Genomic Revolution ETF's 10% weekly surge and Palantir's 13% drop as a lens, they discuss why general partners are hiring operations partners, CFOs, and portfolio success teams earlier than ever. The episode explores the roots of this trend — from larger fund sizes requiring institutional-grade reporting to limited partners demanding more transparency on mark-to-market valuations. Lucas and Luna also break down how this changes the founder-VC relationship, with operations-focused VCs offering more hands-on support but also more rigorous data demands. A must-listen for any founder or emerging manager wondering why their VC meetings now feel more like quarterly board reviews than partnership courtships.

    #VentureCapital #FundOperations #VCIndustry #PortfolioSuccess #LimitedPartners #Fundraising #ARKInvest #Palantir #VCJobs #StartupFunding #Business #Technology #FexingoBusiness #BusinessPodcast #VCPodcast #TermSheets #VCStrategy #OperationalExcellence

    Keep every episode free: buymeacoffee.com/fexingo

    11 min
  • Why VCs Are Investing in Niche AI Copilots for Every Industry

    In this episode of The Venture Capital Podcast, Lucas and Luna examine the shift from general-purpose AI assistants to industry-specific copilots. They discuss how VCs are backing startups building AI tools for under-digitized sectors like construction, agriculture, and logistics. Using recent data—ARKG up 10.5% over five days and a new Facebook AI companion app—they explore why narrow, domain-specific AI models are attracting outsized venture funding. They also cover the economics of copilots: SaaS-like recurring revenue with higher margins, the importance of proprietary data moats, and why investors are willing to pay premium multiples for these startups. The hosts highlight a concrete case: a copilot for construction project management that reduced cost overruns by 15% in early trials. They conclude by asking whether the 'horizontal vs. vertical AI' debate is over, with vertical winning for now.

    #VentureCapital #AICopilots #VerticalAI #StartupInvesting #IndustrySpecificAI #ConstructionTech #AgTech #LogisticsAI #BrianHalligan #BessemerVenture #ARKGenomics #ARCA #FacebookAICompanion #Business #Technology #FexingoBusiness #BusinessPodcast #SeriesAValuation

    Keep every episode free: buymeacoffee.com/fexingo

    10 min
  • Why VCs Are Funding Construction Robotics Startups

    This episode of The Venture Capital Podcast with Fexingo explores a surprising new frontier in venture capital: construction robotics. Lucas and Luna discuss why top-tier VCs are pouring capital into startups that automate building sites, from bricklaying robots to autonomous dozers. They anchor the conversation on a specific case—Menlo Ventures' recent $3 billion fund raise after betting big on Anthropic—and contrast it with the firm's lesser-known bets in construction tech. Lucas shares data on the fragmented $12 trillion global construction industry and how startups are solving labor shortages and productivity stagnation. Luna challenges whether the hardware-heavy model can work in a sector resistant to change. The episode also touches on market signals like the recent pullback in AI stocks and the rise of applied robotics. Is construction the next software? And can VCs resist the lure of shiny AI models to bet on dirt and steel?

    #ConstructionRobotics #VentureCapital #MenloVentures #Anthropic #BuiltRobotics #DustyRobotics #ConstructionTech #Proptech #RoboticsStartups #Business #Technology #FexingoBusiness #BusinessPodcast #VCPodcast #StartupInvesting #TermSheets #AIInfrastructure #LaborShortage

    Keep every episode free: buymeacoffee.com/fexingo

    11 min
  • Why VCs Are Pivoting From AI Models to AI Infrastructure

    In this episode of The Venture Capital Podcast with Fexingo, Lucas and Luna explore why top venture firms are shifting their focus from funding AI model companies to investing in the physical and digital infrastructure that powers them. They break down the recent GPU supply glut, the rise of data-center REITs, and the strategic pivot of firms like a16z and Sequoia toward energy, networking, and compute. Plus, they analyze a funding round for a startup building modular data centers and what it signals about the next wave of AI investment.

    #VentureCapital #AI #AIIinfrastructure #DataCenters #GPU #NVIDIA #a16z #SequoiaCapital #ModularDataCenters #Business #Technology #Startups #Investing #FexingoBusiness #BusinessPodcast #TheVentureCapitalPodcast #TermSheets #StartupInvesting

    Keep every episode free: buymeacoffee.com/fexingo

    8 min
  • The Founder Friendliness Trap in Venture Capital

    In Episode 69 of The Venture Capital Podcast, Lucas and Luna dissect the concept of 'founder friendliness' and how VCs leverage it as a strategic tool. Drawing on June 2026 data, they explore why supposedly friendly terms can lock founders into unfavorable structures, using recent cases like Palantir's slide and Airbnb's steady performance. Lucas explains how VCs use narrative control to shape perceived friendliness, while Luna questions whether the term has become a marketing gimmick. They examine term sheet clauses, reference checks, and exit scenarios, offering concrete insights for founders navigating venture deals. The episode includes a brief, organic mention of listener support that keeps the show ad-free.

    #FounderFriendliness #VentureCapital #TermSheets #LucasAndLuna #BusinessPodcast #FexingoBusiness #StartupInvesting #VCStrategy #Palantir #Airbnb #BusinessAndTechnology #FounderMythology #VCFirmDynamics #StartupFunding #NegotiationTactics #InvestorRelations #BoardSeats #ExitStrategy

    Keep every episode free: buymeacoffee.com/fexingo

    10 min
  • Why VCs Are Tracking Revenue Concentration in 2026

    In this episode of The Venture Capital Podcast, Lucas and Luna explore why top-tier VCs are now scrutinizing revenue concentration as a key risk metric in 2026. They break down a specific case study—a B2B SaaS startup that hit $10 million ARR but had 70% of revenue from a single enterprise client—and show how a diversification clause is quietly appearing in term sheets. With Amazon's Alexa+ expansion, SpaceX's compute deal with Reflection AI, and a 4.7% weekly gain in genomics ETF ARKG providing context, the hosts discuss how VCs are using revenue concentration thresholds to adjust valuations and protect downside. They also examine the link between customer dependency and liquidity preferences, offering practical advice for founders negotiating their next round. Tune in for a specific, actionable take on a trend that's reshaping early-stage investing.

    #RevenueConcentration #VentureCapital #TermSheets #StartupInvesting #DiversificationClause #B2BSaaS #CustomerConcentration #LiquidationPreference #SeriesA #Valuation #ARKG #Genomics #AmazonAlexa #SpaceX #ReflectionAI #Business #FexingoBusiness #BusinessPodcast

    Keep every episode free: buymeacoffee.com/fexingo

    10 min

About The Venture Capital Podcast with Fexingo: VCs, Term Sheets, and Startup Investing

From the publisher's feed

Lucas and Luna sit across from each other at a Sand Hill Road conference table, a term sheet between them, dissecting the mechanics of venture capital. Each episode of The Venture Capital Podcast with Fexingo is a real-time examination of startup investing: the arithmetic of liquidation preferences, the nuance of anti-dilution clauses, the signal in a down round. They never opine for the sake of opinion. Instead, they pull live data — deal flow from PitchBook, valuation trends from Carta, IPO filings from the SEC — and ask the questions a thoughtful investor would ask: What does this cap table tell us about founder alignment? How do these LP terms shift the fund's risk profile? Is this market multiple justified by the unit economics? Lucas, with his journalist's precision, sets the scene: a round closes, a unicorn flatpacks, a new fund announces. Luna, the engaged interlocutor, challenges assumptions, pokes at the fine print, and connects the numbers to the people behind them. They name names — Accel, Sequoia, a16z — but never for hype; always for the lesson embedded in the deal. This show is for founders who've heard 'market standard' one too many times, VCs who want to sharpen their thesis, and anyone who believes that the best venture conversations are about structure, not spin. What happens when the term sheet you're handed isn't the one you thought you'd see?